---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-25-000136"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:13:52.364146+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BeOne Medicines files STAR Interim Report; details R&D spend by key products for H1 2025

## Summary
- Total R&D expenses $1,007M for H1 2025, up from $915M in H1 2024.
- BCL2 inhibitor (BGB-11417) R&D spending surged to $94M from $39M YoY.
- CDAC (BGB-16673) R&D increased to $27M from $6M; CDK4 (BGB-43395) to $10M from $2M.
- Zanubrutinib R&D flat at $63M; Tislelizumab R&D up to $40M from $34M.
- Filing includes PRC GAAP vs U.S. GAAP reconciliation for share-based comp, income taxes, leasing.

## SEC filing metadata
- accession: 0001651308-25-000136
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000136/0001651308-25-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000136/bgne-20250829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-25-000136
- JSON: https://secwatch.observer/filing/0001651308-25-000136.json
- Plain text: https://secwatch.observer/filing/0001651308-25-000136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.